 |
|
Pneumococcal Conjugate Vaccine
Impact on Otitis Media and Otolaryngology
Charles D. Bluestone, MD
From the Department of Pediatric Otolaryngology, University of Pittsburgh
School of Medicine, Children's Hospital of Pittsburgh, Pittsburgh, Pa.
Corresponding author and reprints: Charles D. Bluestone, MD, Department
of Pediatric Otolaryngology, Children's Hospital of Pittsburgh, 3705 Fifth
Ave at DeSoto Street, Pittsburgh, PA 15213.
Arch Otolaryngol Head Neck Surg. 2001;127:464-467.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In February 2000, the new 7-valent pneumococcal polysaccharide-protein
conjugate vaccine (PCV7) (Prevnar; Wyeth Lederle Vaccines, Pearl River, NY)
was approved by the Food and Drug Administration (FDA) for the prevention
of invasive pneumococcal disease (eg, meningitis and bacteremia) in infants
and young children. This long-awaited event has received widespread applause
from pediatric infectious disease experts who anticipate a dramatic decrease
in these potentially fatal serious infections as the infants and young children
who are at high risk become immunized.1, 2
The Centers for Disease Control and Prevention Advisory Committee on Immunization
Practices (ACIP) recommends that the vaccine be given to all infants aged
2 to 23 months and to children aged 24 to 59 months who are at increased risk
for pneumococcal disease, such as those who have sickle cell disease, human
immunodeficiency disease virus infection, and other immunocompromising or
chronic medical conditions.3 The ACIP also
recommends . . . [Full Text of this Article]OUTCOMES OF THE CLINICAL TRIALS
ANTICIPATED IMPACT OF CONJUGATE VACCINE ON AOM AND ITS SUPPURATIVE
COMPLICATIONS
ROLE OF THE OTOLARYNGOLOGIST
CONCLUSIONS
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Prevention of Meningitis: Cochlear Implants and Inner Ear Abnormalities
Bluestone
Arch Otolaryngol Head Neck Surg 2003;129:279-281.
FULL TEXT
|
